Polyion complex composition and use therefor

Abstract

A PIC composition according to the present disclosure includes a host molecule and a complex containing the host molecule. The complex includes a cationic polymer and an anionic polymer.

Description

Polyion complex composition and use thereof

[0001] The present invention relates to a polyion complex composition and its use.

[0002] Pressure ulcers (bed sores) are a disease whose incidence increases with aging. The prevalence of pressure ulcers is particularly high among frail elderly people, and they are very costly for people with chronic diseases, leading to increased awareness of preventive treatment. Pressure ulcers are also said to be the third most costly disease after cancer and cardiovascular disease. As such, pressure ulcers are a disease that should be given serious attention in an aging society, and in recent years, active efforts have been made to develop wound dressings for the treatment or management of pressure ulcers.

[0003] For example, Non-Patent Document 1 discloses PIC (polyion complex) nanoparticles encapsulating the antibiotic Polymyxin B. Non-Patent Document 2 discloses PIC using chitosan.

[0004] European Polymer Journal, 87, 478-486, 2017Journal of Biological Macromolecules, 227, 524-534, 2023

[0005] However, PICs are expected to be used in a variety of applications, and the PICs described in Non-Patent Documents 1 and 2 alone cannot meet the needs of the industrial world, so new PICs are desired.

[0006] Therefore, one aspect of the present invention aims to provide a novel PIC composition that can exhibit the properties of the active ingredient.

[0007] A polyion complex composition according to one embodiment of the present invention includes a host molecule and a complex containing the host molecule, and the complex includes a cationic polymer and an anionic polymer.

[0008] Furthermore, a polyion complex composition for an antibacterial material according to one embodiment of the present invention comprises an antibacterial agent and a complex containing the antibacterial agent, and the complex comprises a cationic polymer having antibiofilm activity and an anionic polymer having anti-inflammatory properties.

[0009] Furthermore, a method for preparing a polyion complex composition according to one aspect of the present invention includes a mixing step of mixing a host molecule, a cationic polymer, and an anionic polymer.

[0010] According to one aspect of the present invention, a novel PIC composition can be provided. Furthermore, since the PIC composition according to one aspect of the present invention has the composition of the present invention, the PIC composition can be decomposed under a desired environment. This allows the host molecule to be released from the PIC composition, allowing the properties of the host molecule to be exhibited under a desired environment.

[0011] 1 is a diagram showing the number particle size distribution of the PIC obtained in Evaluation Example 1. FIG. 2 is a diagram showing the results of observation by scanning electron microscopy of the PIC obtained in Evaluation Example 1. FIG. 3 is a diagram showing the evaluation results of the stability and sustained release of the model PIC composition obtained in Evaluation Example 3. FIG. 4 is a diagram showing the results of comparison of the amounts of cyclodextrin contained in the fourth supernatant and the dialysate. FIG. 5 is a diagram showing the results of comparison of the amounts of cyclodextrin contained in the fourth supernatant and the dialysate. FIG. 6 is a diagram showing the results of a total ion chromatogram (TIC) of Bicine dialysate. FIG. 7 is a diagram showing the results of TIC of an aqueous sodium acetate solution dialysate. FIG. 8 is a diagram showing the results of TIC of the fourth supernatant. FIG. 9 is a diagram showing the results of TIC of an aqueous cyclodextrin solution. FIG. 10 is a diagram showing the results of a mass spectrum (MS spectrum) of Bicine dialysate. FIG. 11 is a diagram showing the MS spectrum of an aqueous sodium acetate solution dialysate. FIG. 12 is a diagram showing the MS spectrum of the fourth supernatant. FIG. 13 is a diagram showing the MS spectrum of an aqueous cyclodextrin solution. FIG. 14 is a diagram showing the results of scanning electron microscopy (magnification: 500x) of the antibacterial sheet of Example 5. FIG. 1 shows the results of scanning electron microscope observation (magnification: 100x) of the antibacterial sheet of Example 5. FIG. 2 shows the results of scanning electron microscope observation (magnification: 500x) of the antibacterial sheet of Comparative Example 4. FIG. 3 shows the results of scanning electron microscope observation (magnification: 100x) of the antibacterial sheet of Comparative Example 4. FIG. 4 shows the results of measuring the biofilm formation inhibitory activity concentration of Example 7. FIG. 5 shows the results of measuring the biofilm destruction activity concentration of Example 8.

[0012] One aspect of the present invention will be described below, but the present invention is not limited thereto. The present invention is not limited to the respective configurations described below, and various modifications are possible within the scope of the present specification. Furthermore, embodiments and examples obtained by appropriately combining the technical means disclosed in the respective embodiments and examples are also included in the technical scope of the present invention. In this specification, "A to B" indicates A or more and B or less, unless otherwise specified. Furthermore, the expression "A-B" also indicates A or more and B or less, unless otherwise specified.

[0013] [1. PIC Composition] A polyion complex composition according to one embodiment of the present invention (hereinafter may be referred to as a "PIC composition") includes a host molecule and a complex containing the host molecule, and the complex (hereinafter may be referred to as a "PIC") includes a cationic polymer and an anionic polymer.

[0014] The PIC composition according to one embodiment of the present invention can be disintegrated in a desired environment (e.g., an environment with a pH higher than 6.0) by combining a cationic polymer and an anionic polymer, thereby releasing the host molecule encapsulated in the complex containing the cationic polymer and the anionic polymer from the PIC composition, allowing the host molecule to exhibit its properties in the desired environment.

[0015] Furthermore, in the PIC composition according to one embodiment of the present invention, the active ingredient is a host molecule, so that the possibility of drug-resistant bacteria emerging is low.

[0016] (Host Molecule) In this specification, a host molecule is a molecule that includes a guest molecule to form an inclusion compound. The guest molecule can be appropriately set to a molecule that can be included by the host molecule. Examples of guest molecules include alkyl groups of signaling substances such as AHLs (acylated homoserine lactones), hydrophobic moieties such as aromatic rings, and substances that can interact with lipopolysaccharides.

[0017] Host molecules include substances such as cyclodextrin compounds, calixarenes, crown ethers, carbon nanotubes, zeolites, MOFs (Metal Organic Frameworks), and mesoporous silica. Cyclodextrin compounds are preferred as host molecules. MOFs are materials that have a porous coordination network structure with a high surface area due to the interaction between metals and organic ligands.

[0018] The cyclodextrin compounds include cyclodextrin and its derivatives. Examples of cyclodextrins include α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin. Examples of cyclodextrin derivatives include cyclodextrins having at least one substituent selected from the group consisting of methyl, methoxy, triacetyl, hydroxypropyl, aminated, aminoacylated, and p-toluenesulfonyl groups. Among these, α-cyclodextrin is particularly preferred. This is because α-cyclodextrin has a smaller pore size of approximately 0.47 nm than β-cyclodextrin (approximately 0.62 nm), making it easier to selectively encapsulate signal molecules of Gram-negative bacteria. Furthermore, its high aqueous solubility reduces precipitation and irritation in the unencapsulated state. Furthermore, compared to β-cyclodextrin, α-cyclodextrin is metabolized more rapidly in the body and has a lower risk of bioaccumulation, making it safer. For these reasons, α-cyclodextrin is particularly useful in the antibacterial and antibiofilm applications of the present invention.

[0019] The host molecule may be of one type or of two or more types.

[0020] There is no limitation on the content of the host molecule in the PIC composition according to one embodiment of the present invention. In order to improve the anti-inflammatory or anti-biofilm properties of the PIC composition, the content of the host molecule in the PIC composition is preferably 1% by mass or more relative to 100% by mass of the PIC composition.

[0021] (Cationic Polymer) Examples of the cationic polymer include cationic polymers having at least one of deodorizing, antibacterial, antibiofilm, and anti-inflammatory properties. Examples of the cationic polymer include polylysine, chitosan, and cationized gelatin. The cationic polymer may be one type or two or more types.

[0022] As used herein, the term "anti-biofilm activity" refers to the activity of inhibiting the formation of a biofilm or the activity of destroying a biofilm.

[0023] In terms of having antibacterial and antibiofilm activities, the cationic polymer is preferably polylysine. In terms of improving antibacterial and antibiofilm activities, the concentration of the cationic polymer is preferably 100 ppm or more, more preferably 300 ppm or more.

[0024] From the viewpoint of ease of forming a PIC, the degree of polymerization of the cationic polymer is preferably 2 or more, more preferably 10 or more, and even more preferably 20 or more. The degree of polymerization of a polymer such as a cationic polymer can be measured by a known method such as gel permeation chromatography.

[0025] (Anionic polymer) Examples of the anionic polymer include anionic polymers having at least one of deodorizing, antibacterial, antibiofilm, and anti-inflammatory properties. Examples of the anionic polymer include alginic acid or its salts (e.g., salts of sodium, magnesium, potassium, calcium, etc.), gelatin, hyaluronic acid, etc. The anionic polymer may be one type or two or more types.

[0026] In terms of anti-inflammatory properties, the anionic polymer is preferably alginic acid or a salt thereof. Furthermore, the alginic acid salt is preferably water-soluble in order to inhibit gelation. For example, among alginic acid salts, sodium salt or potassium salt is preferred, with sodium salt being more preferred. Furthermore, in terms of improving anti-inflammatory properties, the concentration of the anionic polymer is preferably 100 ppm or more.

[0027] In one example of a preferred embodiment of the PIC composition of the present invention, the cationic polymer concentration is 100 ppm or more and the anionic polymer concentration is 100 ppm or more, and the PIC composition has excellent antibacterial, antibiofilm, and anti-inflammatory properties.

[0028] The degree of polymerization of the anionic polymer is preferably 10 or more, more preferably 50 or more, and even more preferably 100 or more, from the viewpoint of ease of forming a PIC.

[0029] In the PIC composition according to one embodiment of the present invention, the content ratio of the cationic polymer to the anionic polymer (cationic polymer / anionic polymer) is preferably 0.1 or more, and more preferably 0.3 or more, from the viewpoint of ease of PIC formation, etc., and the content ratio of the cationic polymer to the anionic polymer (cationic polymer / anionic polymer) is preferably 10.0 or less, and more preferably 5.0 or less, from the viewpoint of ease of PIC formation, etc. Therefore, the content ratio of the cationic polymer to the anionic polymer (cationic polymer / anionic polymer) is preferably 0 or more and 10.0 or less, and more preferably 0.3 or more and 5.0 or less.

[0030] (Preferred Combination of Cationic Polymer and Anionic Polymer) In the PIC composition according to one aspect of the present invention, it is preferred that the cationic polymer is polylysine and the anionic polymer is alginic acid or a salt thereof, in terms of improving anti-inflammatory and anti-biofilm properties and making the PIC composition more susceptible to disintegration in an environment with a pH above 6.0.

[0031] (Other Components) The PIC composition according to one embodiment of the present invention may contain other components in addition to the host molecule, cationic polymer, and anionic polymer. Examples of the other components include inclusion compounds, antibacterial compounds, deodorizing compounds, biofilm formation inhibitory compounds, and anti-inflammatory compounds.

[0032] (Characteristics of PIC Composition) The PIC composition according to one embodiment of the present invention is resistant to disintegration in an environment where the pH is less than 6.0. Herein, the "disintegration" of the PIC composition refers to a decrease in the physical interactions between the different polymer species constituting the PIC, resulting in a loosening of the polymer network between the different polymer species. On the other hand, in an environment where the pH is 6.0 or higher and 9.0 or lower (e.g., pH 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, or 9.0), the PIC composition is prone to disintegration, and the host molecules are released from the PIC composition. This allows the properties of the host molecules (e.g., clathrate, anti-inflammatory, and anti-biofilm activity) to be exhibited in the desired environment. Furthermore, the PIC composition of the present invention does not require a crosslinking process using a covalent crosslinking agent or external stimuli, since the cationic polymer and the anionic polymer self-assemble to form a complex through electrostatic interaction. This configuration simplifies the manufacturing process and avoids concerns about cytotoxicity due to residual crosslinking agents. Furthermore, because they lack a covalent bond network, PIC compositions maintain the property of readily disintegrating under the desired environment and rapidly releasing the encapsulated host molecules. The formation of such PIC compositions can be confirmed or detected by various physicochemical techniques. For example, the disintegration behavior can be captured by gradually changing the pH of a solution containing the PIC composition and observing the changes in its physical properties. Specifically, particle formation or dissociation due to interactions between polymers can be visually and quantitatively evaluated by measuring the change in turbidity with pH.

[0033] Furthermore, the PIC composition according to one embodiment of the present invention can be uniformly dispersed in a target environment, thereby allowing the properties of the host molecules released by the breakdown of the PIC composition to be uniformly exhibited in the target environment.

[0034] (Method for Preparing PIC Composition) The method for preparing a PIC composition includes a mixing step of mixing the host molecule, the cationic polymer, and the anionic polymer. The mixing step can be performed, for example, by mixing a solution containing a host molecule, a solution containing an anionic polymer, and a solution containing a cationic polymer by stirring. After preparing a mixed solution (e.g., an aqueous solution) containing a host molecule and a cationic polymer, a solution (e.g., an aqueous solution) containing an anionic polymer may be added to the mixed solution and mixed by stirring. Furthermore, the water contained in the aqueous solution is preferably pure water. The PIC composition may be composed of a substance that improves the dispersion stability of PIC, such as an inorganic salt, a buffer, or a hydrophilic polymer.

[0035] In order to suppress aggregation of the prepared PIC composition, it is preferable to further mix an acid in the mixing step. Examples of the acid include inorganic acids such as hydrochloric acid and sulfuric acid; and organic acids such as formic acid, citric acid, and acetic acid. In order to further suppress aggregation of the PIC composition, it is preferable that the acid is an organic acid.

[0036] The amount of acid used in the mixing step can be appropriately selected depending on the type or amount of the host molecule, cationic polymer, or anionic polymer used.

[0037] The order of mixing the materials in the mixing step is not particularly limited. However, in terms of further suppressing aggregation of the PIC composition, it is preferable to mix a cationic polymer with an acid, and then mix the resulting mixture with a host molecule, and then mix the resulting mixture with an anionic polymer.

[0038] (Uses of PIC Composition) One aspect of the present invention also includes a deodorant, a biofilm formation inhibitor, or an antibacterial material such as a wound dressing, which contains the PIC composition according to one aspect of the present invention.

[0039] Sewage or liquids containing malodorous substances with an ammonia smell contain volatile organic compounds, which are malodorous components. The presence of ammonia also results in a pH of 6.0 or higher. By spraying a deodorizer according to one aspect of the present invention onto an object to be deodorized, such as sewage or a liquid containing malodorous substances with an ammonia smell, the PIC composition disintegrates in the object to be deodorized, releasing the host molecules in the PIC composition. The volatile organic compounds are then encapsulated in the released host molecules, thereby deodorizing the object.

[0040] A biofilm formation inhibitor according to one embodiment of the present invention can be used in environments where biofilms are likely to form, such as living environments such as kitchens, bathrooms, toilets, and drains; medical environments such as medical devices or cleaning machines for cleaning medical devices; and dental environments such as dental devices used for dental treatment. A biofilm formation inhibitor according to one embodiment of the present invention is applied to a target site, and the host molecules in the PIC composition are released in an environment with a pH of 6.0 or higher. The released host molecules then inhibit biofilm formation or destroy the biofilm at the target site. Prior to using the biofilm formation inhibitor, it is preferable to adjust the pH of the target site to between 6.5 and 9.0.

[0041] The antibacterial material according to one embodiment of the present invention can be used in an environment where it is desired to inhibit or suppress the growth of bacteria (e.g., a wound site). Examples of such bacteria include bacteria belonging to the genus Pseudomonas such as Pseudomonas aeruginosa, bacteria belonging to the genera Candida and Aspergillus, gram-negative bacteria such as Escherichia coli and bacteria that have acquired drug resistance, bacteria belonging to the genus Staphylococcus such as Staphylococcus aureus, gram-positive bacteria such as streptococci and bacteria that have acquired drug resistance, etc.

[0042] Examples of antibacterial materials include wound dressings. It is known that in the case of chronic wounds, the pH at the wound site is 6.0 or higher. By covering the wound site of a subject with a wound dressing according to one embodiment of the present invention, host molecules are released from the PIC composition at the wound site. The released host molecules then promote wound healing. Because the active ingredient is a host molecule, the likelihood of drug-resistant bacteria emerging is low.

[0043] As used herein, a wound dressing is a material used to cover a wound in order to prevent the wound from worsening, heal the wound, or prevent infection at the wound site. As used herein, wounds include burns, contusions, cuts, ulcers, bedsores, and other wounds formed on the skin or in the oral cavity.

[0044] Examples of dosage forms of the deodorant, biofilm formation inhibitor, or antibacterial material according to one embodiment of the present invention include patches such as sheets, tapes, and poultices, and topical formulations such as powders, granules, liquids, ointments, gels, creams, lotions, aerosols, suspensions, and emulsions. The PIC composition contained in the deodorant, biofilm formation inhibitor, or antibacterial material according to one embodiment of the present invention is often preferably used in sol form. Sol forms (sols containing a polyion complex composition) allow for various processing and administration procedures, such as spraying or dripping, or immersion or impregnation into pads or foams, which has the advantage of facilitating complexation with sheet materials, etc. Furthermore, even after direct application to the affected area or target surface, they can be quickly removed by simple wiping with water or an aqueous solution such as physiological saline, making them easy to handle after use and preferable for hygiene management. A preferred embodiment of the deodorant, biofilm formation inhibitor, or antibacterial material according to the present invention comprises a sol containing a PIC composition.

[0045] (Combination with Dressing Material) The deodorant, biofilm formation inhibitor, or antibacterial material according to one embodiment of the present invention preferably further comprises a dressing material, which facilitates application in the usage environment. When the PIC composition is used as a wound dressing, it is more preferable that the PIC composition be supported on a dressing material, which facilitates wound coverage. Examples of dressing materials include polyurethane foam, gauze, film materials, hydrocolloid preparations, and hydrogels. Polyurethane foam is preferred as the dressing material, as it is easy to support the PIC composition and has good water absorption properties.

[0046] 2. PIC Composition for Antibacterial Materials A polyion complex composition for antibacterial materials according to one embodiment of the present invention (hereinafter, may be referred to as a "PIC composition for antibacterial materials") comprises an antibacterial agent and a complex containing the antibacterial agent, and the complex comprises a cationic polymer having antibiofilm activity and an anionic polymer having anti-inflammatory properties.

[0047] The PIC composition for antibacterial materials according to one embodiment of the present invention can be disintegrated in an environment where bacterial growth is desired to be inhibited or suppressed (e.g., a wound site) by combining a cationic polymer having antibiofilm activity and an anionic polymer having anti-inflammatory properties. As a result, the antibacterial agent contained in the complex containing the cationic polymer and the anionic polymer is released from the PIC composition for antibacterial materials, allowing the antibacterial activity of the antibacterial agent to be exerted in the environment.

[0048] (Antibacterial Agent) Examples of antibacterial agents contained in the PIC composition for antibacterial materials according to one embodiment of the present invention include the host molecule. Examples of the host molecule include the cyclodextrin compounds, calixarenes, crown ethers, carbon nanotubes, zeolites, MOFs (Metal Organic Frameworks), mesoporous silica, and other substances. Examples of guest molecules encapsulated by the host molecule include alkyl groups of signaling substances such as AHLs (acylated homoserine lactones), hydrophobic moieties such as aromatic rings, and substances capable of interacting with lipopolysaccharides. In terms of improving the anti-inflammatory and anti-biofilm properties of the PIC composition for antibacterial materials, the antibacterial agent is preferably the cyclodextrin compound. The antibacterial agent may be one type or two or more types.

[0049] There is no limit to the content of the antibacterial agent in the PIC composition for antibacterial materials according to one embodiment of the present invention. In order to improve the anti-inflammatory or anti-biofilm properties of the PIC composition for antibacterial materials, the content of the antibacterial agent in the PIC composition for antibacterial materials is preferably 1% by mass or more relative to 100% by mass of the PIC composition for antibacterial materials. By incorporating cyclodextrin into the PIC, several useful effects are expected. The synergistic effect of interaction with the cationic polymer can improve antibacterial properties, suppress nonspecific drug exposure to healthy tissues due to controlled drug release, and reduce side effects. Furthermore, multiple functions, such as antibacterial properties, antibiofilm properties, and anti-inflammatory properties, can be simultaneously exhibited by a single component.

[0050] (Cationic Polymers Having Anti-Biofilm Activity) Examples of cationic polymers having anti-biofilm activity include biocompatible polymers such as polylysine, chitosan, and cationized gelatin.

[0051] (Anionic polymers having anti-inflammatory properties) Examples of anionic polymers having anti-inflammatory properties include biocompatible polymers such as alginic acid or its salts (e.g., salts of sodium, magnesium, potassium, calcium, etc.), gelatin, and hyaluronic acid.

[0052] (Preferred Combination of Cationic Polymer and Anionic Polymer) In the PIC composition for antibacterial materials according to one embodiment of the present invention, it is preferred that the cationic polymer having antibiofilm activity is polylysine and the anionic polymer having anti-inflammatory activity is alginic acid or a salt thereof, since the PIC composition is more likely to disintegrate in an environment of pH above 6.0.

[0053] Details of the degree of polymerization and content ratio of the cationic polymer having anti-biofilm activity and the anionic polymer having anti-inflammatory activity are the same as those of the cationic polymer and the anionic polymer in [1. PIC composition], and therefore will not be described again.

[0054] (Other Components) The PIC composition for antibacterial materials according to one embodiment of the present invention may contain other components in addition to the antibacterial agent, the cationic polymer having antibiofilm activity, and the anionic polymer having anti-inflammatory properties.

[0055] (Characteristics of the PIC composition for antibacterial material) The PIC composition for antibacterial material according to one embodiment of the present invention does not disintegrate in an environment with a pH of less than 6.0. On the other hand, in an environment with a pH of 6.0 or higher (e.g., pH 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, or 9.0), the PIC composition for antibacterial material disintegrates, and the antibacterial agent is released from the PIC composition for antibacterial material. This allows the antibacterial agent to exert its antibacterial activity in an environment where it is desired to inhibit or suppress the growth of bacteria (e.g., a wound site).

[0056] Furthermore, the PIC composition for antibacterial materials according to one aspect of the present invention can be uniformly dispersed in an environment where bacterial growth is desired to be inhibited or suppressed (for example, a wound site), thereby allowing the antibacterial activity of the antibacterial agent released by the disintegration of the PIC composition for antibacterial materials to be uniformly exerted in the environment.

[0057] (Method for Preparing a PIC Composition for Antibacterial Materials) The method for preparing a PIC composition for antibacterial materials includes a mixing step of mixing the antibacterial agent, the cationic polymer, and the anionic polymer. The mixing step can be performed, for example, by mixing a solution containing the antibacterial agent, a solution containing the anionic polymer, and a solution containing the cationic polymer by stirring. After preparing a mixed solution (e.g., an aqueous solution) containing the antibacterial agent and the cationic polymer, a solution (e.g., an aqueous solution) containing the anionic polymer may be added to the mixed solution and mixed by stirring.

[0058] It is preferable to further mix an acid in the mixing step, since this can suppress aggregation of the prepared PIC composition for antibacterial materials. Examples of the acid are the same as the examples of the acid described in the section (1. PIC composition) (Preparation method of PIC composition).

[0059] The order of mixing the materials in the mixing step is not particularly limited, but it is preferable to mix a cationic polymer with an acid, and then mix the antibacterial agent with the resulting mixture, and then mix the anionic polymer with the resulting mixture, in order to further suppress aggregation of the PIC composition for antibacterial materials.

[0060] (Antibacterial Material Comprising PIC Composition for Antibacterial Materials) An antibacterial material according to one aspect of the present invention comprises the PIC composition for antibacterial materials.

[0061] The content of the PIC composition for antibacterial materials contained in the antibacterial material can be appropriately selected depending on the dosage form of the antibacterial material, etc. The antibacterial material may be an antibacterial material made of the PIC composition for antibacterial materials.

[0062] Examples of dosage forms of antibacterial materials containing the PIC composition for antibacterial materials according to one embodiment of the present invention include patches such as sheets, tapes, and poultices, and topical formulations such as powders, granules, liquids, ointments, gels, creams, lotions, aerosols, suspensions, and emulsions. The PIC composition for antibacterial materials is often preferably used in sol form. Sol forms (sols containing the PIC composition for antibacterial materials) allow for various processing and administration procedures, such as spraying, dripping, or immersion in pads or foams, which has the advantage of facilitating compounding with sheet materials, etc. Furthermore, even after direct application to the affected area or target surface, the composition can be quickly removed by simple wiping with water or an aqueous solution such as saline, making it easy to handle after use and favorable for hygiene management. A preferred embodiment of the antibacterial material according to the present invention comprises a sol containing the PIC composition for antibacterial materials.

[0063] (Combination with Dressing Material) The antibacterial material according to one embodiment of the present invention preferably further comprises a dressing material, which makes it easier to apply in the environment of use. When the antibacterial material is a wound dressing material, it is more preferable that the antibacterial material further comprises a dressing material, which makes it easier to cover the wound. Examples of dressing materials are the same as the examples of dressing materials that can be contained in the deodorant, biofilm formation inhibitor, or antibacterial material according to one embodiment of the present invention.

[0064] (Method of Treating a Wound) A method of treating a wound according to one aspect of the present invention includes the step of contacting a wound site of a subject with a wound dressing containing the PIC composition for antibacterial materials.

[0065] As used herein, "treating a wound" also includes preventing the wound from worsening, healing the wound, or preventing infection at the wound site.

[0066] The subject may be a human or a non-human animal. Examples of non-human animals include pets such as dogs and cats, livestock such as pigs, cows, goats, sheep, and horses, birds such as chickens, and laboratory animals such as mice, rats, rabbits, and guinea pigs.

[0067] The amount, duration and frequency of use of the wound dressing containing the PIC composition for antibacterial materials can be appropriately selected depending on the severity of the wound, the age, sex and weight of the subject, the dosage form of the wound dressing, etc.

[0068] [Summary] The polyion complex composition according to aspect 1 of the present invention comprises a host molecule and a complex containing the host molecule, and the complex comprises a cationic polymer and an anionic polymer.

[0069] The polyion complex composition according to the second aspect of the present invention may be the polyion complex composition according to the first aspect, in which the cationic polymer and the anionic polymer are self-assembled by electrostatic interaction.

[0070] The polyion complex composition according to Aspect 3 of the present invention may be the polyion complex composition according to Aspect 1 or 2, wherein the host molecule is at least one host molecule selected from the group consisting of cyclodextrin compounds, calixarene, crown ethers, carbon nanotubes, zeolites, MOFs, and mesoporous silica.

[0071] The polyion complex composition according to Aspect 4 of the present invention may be any one of Aspects 1 to 3, wherein the cationic polymer is polylysine.

[0072] A polyion complex composition according to Aspect 5 of the present invention may be any one of Aspects 1 to 3, in which the cationic polymer is polylysine and the anionic polymer is alginic acid or a salt thereof.

[0073] The polyion complex composition according to Aspect 6 of the present invention is any one of Aspects 1 to 5, wherein the polyion complex composition may disintegrate when the pH of the polyion complex composition is 6.5 or more and 9.0 or less.

[0074] The sol according to Aspect 7 of the present invention may be any one of Aspects 1 to 6, and may contain a polyion complex composition.

[0075] A deodorant, biofilm formation inhibitor, or antibacterial material according to an eighth aspect of the present invention comprises the polyion complex composition according to the seventh aspect.

[0076] The deodorant, biofilm formation inhibitor, or antibacterial material according to aspect 9 of the present invention may further comprise a dressing material in accordance with aspect 8.

[0077] The deodorant, biofilm formation inhibitor, or antibacterial material according to Aspect 10 of the present invention may be in the form of a patch or a topical agent in Aspects 8 or 9.

[0078] A polyion complex composition for an antibacterial material according to an eleventh aspect of the present invention comprises an antibacterial agent and a complex containing the antibacterial agent, the complex comprising a cationic polymer having antibiofilm activity and an anionic polymer having anti-inflammatory properties.

[0079] A polyion complex composition for an antibacterial material according to Aspect 12 of the present invention is the polyion complex composition according to Aspect 11, wherein the antibacterial agent is a host molecule.

[0080] A polyion complex composition according to Aspect 13 of the present invention may be the polyion complex composition according to Aspect 12, wherein the host molecule is at least one host molecule selected from the group consisting of cyclodextrin compounds, calixarene, crown ethers, carbon nanotubes, zeolites, MOFs, and mesoporous silica.

[0081] The polyion complex composition for an antibacterial material according to Aspect 14 of the present invention may be any one of Aspects 11 to 13, in which the cationic polymer is polylysine.

[0082] A polyion complex composition for an antibacterial material according to Aspect 15 of the present invention may be any one of Aspects 11 to 14, wherein the cationic polymer is polylysine and the anionic polymer is alginic acid or a salt thereof.

[0083] The polyion complex composition for an antibacterial material according to Aspect 16 of the present invention may be any one of Aspects 11 to 15, and may disintegrate when the pH of the polyion complex composition is 6.5 or more and 9.0 or less.

[0084] An antibacterial material according to a seventeenth aspect of the present invention comprises the polyion complex composition for an antibacterial material according to the sixteenth aspect.

[0085] The antibacterial material according to Aspect 18 of the present invention may be the antibacterial material according to Aspect 17, which is in the form of a patch or a liniment.

[0086] The antibacterial material according to Aspect 19 of the present invention may further include a dressing material in Aspect 18.

[0087] The method for preparing a polyion complex composition according to Aspect 20 of the present invention includes a mixing step of mixing a host molecule, a cationic polymer, and an anionic polymer.

[0088] A method for preparing a polyion complex composition according to Aspect 21 of the present invention may be the same as Aspect 20, except that an acid may be further mixed in the mixing step.

[0089] A method for preparing a polyion complex composition according to Aspect 22 of the present invention may be the same as Aspect 21, in which in the mixing step, the cationic polymer and the acid are mixed together, and then a host molecule is mixed with the resulting mixture, and the anionic polymer is mixed with the resulting mixture.

[0090] A method according to aspect 23 of the present invention is a method for treating a wound, comprising the step of contacting the antimicrobial material according to any one of aspects 17 to 19 to a wound site of a subject.

[0091] Aspect 24 of the present invention may be the method according to aspect 23, wherein the subject is a non-human animal.

[0092] Unless otherwise specified, % means % by mass.

[0093] Evaluation Example 1: Examination of polymer combinations in PIC compositions Polymer combinations in PIC compositions were examined. An aqueous solution containing each cationic polymer shown in Table 1, an aqueous solution containing an anionic polymer, and an aqueous solution containing α-cyclodextrin were mixed to examine whether PIC or α-CD-encapsulated PIC compositions could be formed.

[0094] Reference Example 1 PIC was synthesized by adding dropwise 1.0 mL of an aqueous solution containing 0.1% polylysine (degree of polymerization: 32) as a cationic polymer to 1.0 mL of an aqueous solution containing 0.1% sodium alginate (viscosity: 300-400 cp) as an anionic polymer while stirring.

[0095] Reference Example 2 PIC was synthesized in the same manner as in Reference Example 1, using polylysine (degree of polymerization: 1026-2052) as the cationic polymer and sodium alginate (viscosity: 300-400 cp) as the anionic polymer.

[0096] Example 1: 0.2 mL of a 5.0 mass% aqueous solution of α-cyclodextrin (α-CD) was added to 10 mL of an aqueous solution containing 0.1% sodium alginate (viscosity: 300-400 cp) as an anionic polymer while stirring in a screw tube. Next, 10 mL of an aqueous solution containing 0.1% polylysine (degree of polymerization: 1026-2052) as a cationic polymer was added to the screw tube and stirred to synthesize an α-CD-encapsulated PIC composition. The α-CD-encapsulated PIC composition had a polylysine concentration of 495 ppm, a sodium alginate concentration of 495 ppm, and an α-CD concentration of 495 ppm.

[0097] Example 2: To an aqueous solution containing 1% polylysine (degree of polymerization: 32) as a cationic polymer, equimolar amounts of formic acid were added with stirring. Next, 2.0 mL of a 5.0 mass% aqueous solution of α-cyclodextrin (α-CD) was added to 7.5 mL of this solution with stirring in a screw tube. Next, 45 mL of an aqueous solution containing 0.05% sodium alginate (viscosity: 300-400 cp) as an anionic polymer was added to the screw tube and stirred to synthesize an α-CD-encapsulated PIC composition. The polylysine concentration of the α-CD-encapsulated PIC composition was 1376 ppm, the sodium alginate concentration was 413 ppm, and the α-CD concentration was 1835 ppm.

[0098] Reference Example 3 A PIC was synthesized according to the procedure shown in Reference Example 1 using porcine gelatin (molecular weight: 40 kDa; kDa means 1,000 Da) as the cationic polymer and sodium alginate (viscosity: 300-400 cp) as the anionic polymer.

[0099] Details of the anionic polymers and cationic polymers in Table 1 are as follows: Porcine gelatin (molecular weight 40,000, product name Gelatin from porcine skin, Sigma-Aldrich Corporation) Polylysine (degree of polymerization: 32, product name ε-Poly-L-Lysine, JNC Corporation) Polylysine (degree of polymerization: 1026-2052, product name Poly-L-lysine solution, Sigma-Aldrich Corporation) Sodium alginate (viscosity 300-400 cP, product name Sodium alginate 300-400, Fujifilm Wako Pure Chemical Industries, Ltd.)

[0100] The results of the investigation are shown in Table 1. In Table 1, ◯ indicates that after mixing the cationic polymer, the anionic polymer, and α-CD, the solution became uniformly cloudy and PIC or an α-CD-encapsulated PIC composition was formed. × indicates that even after mixing the cationic polymer, the anionic polymer, and α-CD, the mixed solution remained colorless and transparent, and PIC or an α-CD-encapsulated PIC composition was not formed.

[0101]

[0102] As shown in Table 1, PIC was formed when polylysine (degree of polymerization: 1026-2052) or polylysine (degree of polymerization: 32) was selected as the cationic polymer and sodium alginate was used as the anionic polymer.

[0103] The number particle size distribution of the PIC obtained using polylysine (degree of polymerization: 1026-2052) as the cationic polymer and sodium alginate (viscosity: 300-400 cP) as the anionic polymer is shown in Figure 1, and the results of observation by scanning electron microscope (SEM) are shown in Figure 2. The number particle size distribution was measured using a particle size distribution analyzer ELSZ-2000 (Otsuka Electronics Co., Ltd.). The measurement of the number particle size distribution and observation by SEM were performed on the PIC before purification.

[0104] As shown in Figures 1 and 2, the average number particle size of the resulting PIC was about 140 nm, with a narrow particle size distribution.

[0105] [Evaluation Example 2] Preparation of Model PIC Composition A uranine-encapsulated PIC composition was prepared as a model PIC composition using polylysine (degree of polymerization: 1026-2052) as the cationic polymer and sodium alginate as the anionic polymer. 100 μL of a 3.0 mM uranine aqueous solution was added dropwise to 1.0 mL of a 0.1% sodium alginate aqueous solution and mixed. While stirring, 1.0 mL of a 0.1% polylysine aqueous solution was added dropwise to prepare a uranine-encapsulated PIC composition.

[0106] The prepared uranine-encapsulated PIC composition was purified by dialysis (6-8 kDa), and its stability and sustained release properties at pH 6.0 and 9.0 were evaluated. The dialysates used were MES buffer (2-(N-morpholino)ethanesulfonic acid) buffer, pH 6.0) and Bicine-NaOH buffer (pH 9.0). After 18 hours of dialysis (first dialysis), the buffer was replaced with a new one, and dialysis was performed for 2.5 hours (second dialysis). After the second dialysis, the buffer was replaced with a new one, and dialysis was performed for 3 days (third dialysis).

[0107] The presence of uranine or the uranine-encapsulated PIC composition in the solution outside the dialysis membrane was confirmed by measuring the fluorescence intensity. The measurement results are shown in Figure 3.

[0108] In Figure 3, "1" indicates the fluorescence intensity of the external dialysis solution after the first dialysis using MES buffer solution, "2" indicates the fluorescence intensity of the external dialysis solution after the third dialysis using MES buffer solution and Bicine-NaOH buffer solution, respectively, and "3" indicates the fluorescence intensity of the external dialysis solution after the second dialysis using MES buffer solution.

[0109] As shown in Figure 3, the amount of uranine eluted from the model PIC composition was small at pH 6.0. On the other hand, when the pH of the dialysis solution was changed to 9.0 and dialysis treatment was performed, the amount of uranine eluted from the model PIC composition increased, indicating that PIC is easily degraded at pH 9.0.

[0110] Evaluation Example 3: Synthesis of cyclodextrin-encapsulated PIC composition. 10 mL of a 0.1% by mass sodium alginate solution and 20 μL of a 1.0 M MES buffer solution adjusted to pH 6.0 were added to a 30 mL screw tube and stirred using a stirrer. Next, 0.8 mL of a 5.0% by mass α-cyclodextrin (α-CD) solution was added to the screw tube with stirring. Next, 10 mL of a 0.1% by mass polylysine solution was added to the screw tube and stirred, yielding a solution containing the α-CD-encapsulated PIC composition as a white suspension.

[0111] Evaluation Example 4: Evaluation of sustained release of cyclodextrin The suspension containing the α-CD-encapsulated PIC composition obtained in Evaluation Example 3 was centrifuged at 2000 G for 20 minutes, and the supernatant was removed to wash the α-CDPIC composition (first supernatant). Next, 20.0 mL of ultrapure water was added to the α-CDPIC composition precipitated by centrifugation, and the resulting suspension was centrifuged at 2000 G for 10 minutes, after which the supernatant was removed. This PIC wash was performed three times (second to fourth washes). The supernatant after centrifugation in the fourth wash was analyzed by LC / MS.

[0112] Next, the α-CDPIC composition after the fourth wash was dispersed in 300 μL of ultrapure water, and the resulting dispersion was poured into a dialysis membrane. An Xpress Micro Dialyzer MD300 6-8 kDa was used as the dialysis membrane. Dialysis was then performed for 1 hour against 1.0 mL of 25 mM bicine buffer adjusted to pH 9.0 or 1.0 mL of 25 mM aqueous sodium acetate solution adjusted to pH 4.36. The dialyzed solution was analyzed by LC / MS.

[0113] For comparison, an aqueous solution of cyclodextrin (1 ppm) was analyzed by LC / MS.

[0114] The LC and MS conditions for the LC / MS analysis were as follows: (Liquid Chromatography (LC) Measurement Conditions) Apparatus: Waters ACQUITY UPLC I-Class Analytical column: YMC-UltraHT Hydrosphere C18 (250 mm x 21 mm) Elution conditions: Flow rate 0.2 mL / min Solvent A: Water (containing 0.1% acetic acid) Solvent B: Acetonitrile Details of the elution conditions (gradient of solvents A and B) are shown in Table 2 below. The values ​​for solvents A and B in Table 2 indicate the percentages of solvents A and B contained in the mobile phase (eluent).

[0115]

[0116] (Mass spectrum (MS) measurement conditions) Apparatus: Waters Xevo TQ-XS triple quadrupole mass spectrometer Ionization conditions: ESI positive ion mode

[0117] The results of the LC / MS analysis are shown in Figures 4 to 13.

[0118] Figures 4 and 5 show the results of comparing the amounts of α-CD contained in the quaternary supernatant and the dialysate. Figure 5 shows the results when the amount of α-CD (area value) in the sodium acetate (AcONa) aqueous solution (pH 4.36) dialysate was set to 1. The area values ​​in Figures 4 and 5 were calculated from the TICs in Figures 6 to 9. Here, TIC refers to a chart plotting the sum of peak intensities per mass spectrum against retention time.

[0119] 6 to 9 show [M+H]＋ 6 shows the results for the Bicine (pH 9.0) dialysate, FIG. 7 shows the results for the sodium acetate aqueous solution (pH 4.36) dialysate, FIG. 8 shows the results for the fourth supernatant, and FIG. 9 shows the results for the cyclodextrin aqueous solution (1 ppm).

[0120] 10 to 13 show the MS spectra of each sample. Fig. 10 shows the results for the Bicine (pH 9.0) dialysate, Fig. 11 shows the results for the sodium acetate aqueous solution (pH 4.36) dialysate, Fig. 12 shows the results for the fourth supernatant, and Fig. 13 shows the results for the cyclodextrin aqueous solution (1 ppm).

[0121] As shown in Figures 4 to 13, more α-CD was detected in the bicine (pH 9.0) dialysate than in the sodium acetate (pH 4.36) dialysate. This is thought to be due to the disintegration of the α-CD-encapsulated PIC composition prepared in Evaluation Example 3 at pH 9.0, resulting in the release of α-CD. The released α-CD can promote wound healing, and therefore can be used as a deodorant, biofilm formation inhibitor, or wound dressing.

[0122] Evaluation Example 5: Evaluation of antibacterial activity of α-CD-encapsulated PIC composition The antibacterial activity of the α-CD-encapsulated PIC composition was evaluated. 50 μL of each test substance was mixed with 150 μL of bacterial culture solution on a 96-well plate to adjust the concentration to 62.5 ppm, and the antibacterial activity was evaluated by the colony count method. The incubation temperature was 37°C, the incubation time was 22 hours, and tryptic soy broth was used as the medium. The test strain was NBRC 100650 Pseudomonas putida (a gram-negative bacillus).

[0123] Example 3 The α-CD-encapsulated PIC composition prepared in Example 1 was used as a test substance, and the antibacterial properties of the PIC composition were evaluated according to the procedure shown in Evaluation Example 5.

[0124] Comparative Example 1 As a positive control, silver nitrate (AgNO ３ ) was selected as the test substance and evaluated according to the procedure shown in Evaluation Example 5.

[0125] The evaluation results are shown in Table 3. In Table 3, ND indicates that the substance was not detected.

[0126]

[0127] As can be seen from Table 3, no bacteria were detected in the α-CD-encapsulated PIC composition, and the composition exhibited antibacterial activity equivalent to that of silver nitrate.

[0128] Evaluation Example 6: Evaluation of biofilm formation inhibitory activity of α-CD-encapsulated PIC composition The biofilm formation inhibitory activity of the α-CD-encapsulated PIC composition was evaluated. 50 μL of each test substance was mixed with 150 μL of bacterial culture solution on a 48-well plate to adjust the concentration to 62.5 ppm, and the biofilm formation inhibitory activity was evaluated by the crystal violet method. The incubation temperature was 37°C, the incubation time was 48 hours, and tryptic soy broth was used as the medium. The test strain was NBRC 100650 Pseudomonas putida (a gram-negative bacillus).

[0129] Example 4 Using the α-CD-encapsulated PIC composition prepared in Example 1 as a test substance, the biofilm formation inhibitory activity of the PIC composition was evaluated according to the procedure shown in Evaluation Example 6.

[0130] <Comparative Example 2> Silver nitrate (AgNO) having biofilm formation inhibitory activity ３ ) was selected as the test substance and evaluated according to the procedure shown in Evaluation Example 6.

[0131] The evaluation results are shown in Table 4. ND in Table 4 indicates that no detection was detected, and the biofilm formation rate was calculated using the following method: the amount of biofilm formed when no test substance was administered was set at 100%, and the rate was calculated as the ratio of the amount of biofilm formed when each test substance was administered to the amount of biofilm formed when no test substance was administered.

[0132]

[0133] As can be seen from Table 4, the α-CD-encapsulated PIC composition was AgNO ３ showed higher biofilm formation inhibitory activity than

[0134] Evaluation Example 7: Evaluation of biofilm disruption activity of α-CD-encapsulated PIC composition The biofilm disruption activity of the α-CD-encapsulated PIC composition was evaluated. 200 μL of bacterial culture solution was placed in a 48-well plate, and a biofilm was allowed to form. The bacterial culture solution was then removed, and 200 μL of each test substance was added, and the biofilm disruption activity was evaluated by the crystal violet method. The incubation temperature was 37°C, the incubation time for biofilm formation was 48 hours, and the incubation time for evaluating biofilm disruption activity was 24 hours. Tryptic soy broth was used as the medium. The test strain was NBRC 100650 Pseudomonas putida (a gram-negative bacillus).

[0135] Example 4 The α-CD-encapsulated PIC composition prepared in Example 2 was used as a test substance, and the biofilm-destructive activity of the PIC composition was evaluated according to the procedure shown in Evaluation Example 7.

[0136] <Comparative Example 3> As a comparative example, silver nitrate (AgNO ３ ) was selected as the test substance and evaluated according to the procedure shown in Evaluation Example 7.

[0137] The evaluation results are shown in Table 5.

[0138] As can be seen from Table 5, the α-CD-encapsulated PIC composition was AgNO ３ showed significantly higher biofilm destruction activity than

[0139] Evaluation Example 8 Preparation of an antibacterial sheet by combining an α-CD-encapsulated PIC composition The preparation of an antibacterial sheet by combining an α-CD-encapsulated PIC composition was investigated.

[0140] Example 5 An antibacterial sheet was prepared by impregnating 30 mg of Bayaten, a commercially available wound dressing and protective material, with 200 μL of the α-CD-encapsulated PIC composition prepared in Example 2, and freeze-drying the mixture overnight.

[0141] Comparative Example 4 As a comparative control, 30 mg of Viaten, a commercially available wound dressing and protective material, was impregnated in 200 μL of ultrapure water and freeze-dried overnight to prepare a wound dressing.

[0142] Figures 14 and 15 are scanning electron microscope (SEM) photographs of the antibacterial sheet produced in Example 5. Figures 16 and 17 are scanning electron microscope (SEM) photographs of the antibacterial sheet produced in Comparative Example 4.

[0143] 14 to 17, it was confirmed that the α-CD-encapsulated PIC composition was carried on the surface and inside of the antibacterial sheet prepared in Example 5.

[0144] Evaluation Example 9: Evaluation of antibacterial properties of antibacterial sheets containing α-CD-encapsulated PIC compositions. Each test substance was placed in 200 μL of bacterial culture solution, and the antibacterial properties were evaluated by the colony count method. The incubation temperature was 37°C, the incubation time was 24 hours, and tryptic soy broth was used as the medium. The test bacterial strain was NBRC 100650 Pseudomonas putida (a gram-negative bacillus).

[0145] Example 6 The antibacterial sheet prepared in Example 5 was used as a test substance and evaluated according to the procedure shown in Evaluation Example 9.

[0146] Comparative Example 5 The antibacterial sheet prepared in Comparative Example 4 was used as a test substance and evaluated according to the procedure shown in Evaluation Example 9.

[0147] The evaluation results are shown in Table 6. In Table 6, * indicates the percentage of the number of colonies formed relative to the number of colonies formed on the antibacterial sheet produced in Comparative Example 4, which is taken as 100%.

[0148]

[0149] As can be seen from Table 6, the antibacterial sheet containing the α-CD-encapsulated PIC composition exhibited antibacterial properties.

[0150] Evaluation Example 10: Evaluation of the biofilm formation inhibitory activity of α-CD-encapsulated PIC composition against Pseudomonas aeruginosa. The biofilm formation inhibitory activity of the α-CD-encapsulated PIC composition against Pseudomonas aeruginosa was evaluated. In a 48-well plate, 60 μL of the test substance was mixed with 240 μL of bacterial culture solution, and the biofilm formation inhibitory activity concentration was evaluated by measuring the absorbance at 570 nm using the crystal violet method. The incubation temperature was 37°C, the incubation time was 24 hours, and Trypto-Soya Broth was used as the medium. The test strain was NBRC 13275 Pseudomonas aeruginosa.

[0151] Example 7 The α-CD-encapsulated PIC composition prepared in Example 2 was used as a test substance, and the PIC composition was diluted to evaluate the biofilm formation inhibitory activity concentration according to the procedure shown in Evaluation Example 10.

[0152] FIG. 18 shows the results of Example 7 showing the biofilm formation inhibitory activity concentration.

[0153] 18, a rapid increase in absorbance was observed at a concentration of 1 / 40 or less of the initial concentration. Therefore, it was confirmed that the α-CD-encapsulated PIC composition inhibited the formation of Pseudomonas aeruginosa biofilms at a concentration of 1 / 40 of the initial concentration.

[0154] Evaluation Example 11: Evaluation of the biofilm-disrupting activity of α-CD-encapsulated PIC composition against Pseudomonas aeruginosa The biofilm-disrupting activity of the α-CD-encapsulated PIC composition against Pseudomonas aeruginosa was evaluated. 240 μL of bacterial culture solution was placed in a 48-well plate, and a biofilm was allowed to form. The bacterial culture solution was then removed, and 200 μL of each test substance was added. The biofilm-disrupting activity concentration was evaluated by measuring the absorbance at 570 nm using the crystal violet method. The incubation temperature was 37°C, the incubation time for biofilm formation was 24 hours, and the incubation time for evaluating biofilm-disrupting activity was 24 hours. Trypto-Soya Broth was used as the medium. The test strain was NBRC 13275 Pseudomonas aeruginosa.

[0155] Example 8 The α-CD-encapsulated PIC composition prepared in Example 2 was used as a test substance, and the PIC composition was diluted to evaluate the biofilm-destructive activity concentration according to the procedure shown in Evaluation Example 11.

[0156] FIG. 19 shows the results of Example 8 showing the biofilm-destroying activity concentration.

[0157] 19, no increase in absorbance was observed at concentrations of 1 / 100 or less of the initial concentration. Therefore, it was confirmed that the α-CD-encapsulated PIC composition destroys Pseudomonas aeruginosa biofilms at 1 / 100 of the initial concentration.

[0158] The PIC composition according to one aspect of the present invention can release the active ingredient contained therein in a target environment and exhibit the properties of the active ingredient in the target environment, and therefore can be used in the medical field as well as in general living environments.

Claims

1. A polyion complex composition comprising a host molecule and a complex containing the host molecule, the complex comprising a cationic polymer and an anionic polymer.

2. The polyion complex composition according to claim 1, wherein the cationic polymer and the anionic polymer are self-assembled by electrostatic interaction.

3. The polyion complex composition according to claim 1 or 2, wherein the host molecule is at least one host molecule selected from the group consisting of cyclodextrin compounds, calixarene, crown ether, carbon nanotubes, zeolite, MOF, and mesoporous silica.

4. The polyion complex composition according to any one of claims 1 to 3, wherein the cationic polymer is polylysine.

5. The polyion complex composition according to any one of claims 1 to 3, wherein the cationic polymer is polylysine, and the anionic polymer is alginic acid or a salt thereof.

6. The polyion complex composition according to any one of claims 1 to 5, wherein the polyion complex composition disintegrates when the pH of the polyion complex composition is 6.5 or more and 9.0 or less.

7. A sol comprising the polyion complex composition according to any one of claims 1 to 6.

8. A deodorizer, biofilm formation inhibitor or antibacterial material comprising the sol according to claim 7.

9. The deodorant, biofilm formation inhibitor or antibacterial material according to claim 8, further comprising a dressing material.

10. The deodorant, biofilm formation inhibitor or antibacterial material according to claim 8 or 9, which is in the form of a patch or liniment.

11. A polyion complex composition for use as an antibacterial material, comprising an antibacterial agent and a complex containing the antibacterial agent, the complex comprising a cationic polymer having anti-biofilm activity and an anionic polymer having anti-inflammatory properties.

12. The polyion complex composition for antibacterial materials according to claim 11, wherein the antibacterial agent is a host molecule.

13. The polyion complex composition for antibacterial materials according to claim 12, wherein the host molecule is at least one host molecule selected from the group consisting of cyclodextrin compounds, calixarene, crown ethers, carbon nanotubes, zeolites, MOFs, and mesoporous silica.

14. The polyion complex composition for antibacterial materials according to any one of claims 11 to 13, wherein the cationic polymer is polylysine, and the anionic polymer is alginic acid or a salt thereof.

15. The polyion complex composition for antibacterial materials according to any one of claims 11 to 14, which disintegrates when the pH of the polyion complex composition is 6.5 or more and 9.0 or less.

16. An antibacterial material comprising the polyion complex composition for antibacterial materials according to any one of claims 11 to 15.

17. The antimicrobial material of claim 16, further comprising a dressing.

18. A method for preparing a polyion complex composition, comprising a mixing step of mixing a host molecule, a cationic polymer, and an anionic polymer.

19. The preparation method according to claim 18, wherein an acid is further mixed in the mixing step.

20. The preparation method according to claim 19, wherein in the mixing step, the cationic polymer and the acid are mixed, and then a host molecule is mixed therewith, and the resulting mixture is mixed with the anionic polymer.

Images